

REMARKS


The Examiner has made restriction required of the claims under 35 U.S.C. 121. The Applicants elect with traverse Group V described on page 2 of the Restriction Requirement as compounds according to claim 1 of formula I, wherein B is N, C is C and D is N. The Applicants respectfully request that the restriction be withdrawn at least with respect to Groups II-V as all compounds contained within these groups all fall within class 544. It would therefore not present a significant burden on the Examiner to examine these groups.

Without acquiescence to the propriety of the restriction requirement, the Applicants have amended the claims to comport with the restriction requirement. Claim 1 has been amended to comport with the elected group. Claims 6-9 have been cancelled.

Applicants submit that the application is in condition for allowance. Early Notice of Allowance is respectfully requested. Should there be any issues that have not been addressed to the Examiners satisfaction, Applicants invite the Examiner to contact the undersigned attorney.

If any fees other than those submitted herewith are due in connection with this response, including the fee for any required extension of time (for which Applicants hereby petition), please charge such fees to Deposit Account No. 500329.

Respectfully submitted,



Vincent P. Liptak
Agent For Applicants
Registration No. 53,225

Date: April 29, 2005

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 622-7908
Fax: (858) 678-8233